Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]J. Arrowsmith and P. Miller: Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov, 12 (8), 569 (2013)

  • [2]M. E. Bunnage: Getting pharmaceutical R&D back on target. Nat Chem Biol, 7 (6), 335-9 (2011)

  • [3]D. C. Swinney: Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov, 3 (9), 801-8 (2004)

  • [4]P. J. Tummino and R. A. Copeland: Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry, 47 (20), 5481-92 (2008)

  • [5]R. A. Copeland, D. L. Pompliano and T. D. Meek: Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov, 5 (9), 730-739 (2006)

  • [6]J. D. Hothersall, A. J. Brown, I. Dale and P. Rawlins: Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses? Drug Discovery Today

  • [7]C. Hoffmann, M. Castro, A. Rinken, R. Leurs, S. J. Hill and H. F. Vischer: Ligand Residence Time at G-protein-Coupled Receptors-Why We Should Take Our Time To Study It. Mol Pharmacol, 88 (3), 552-60 (2015)

  • [8]F. Schiele, P. Ayaz and A. Mueller-Fahrnow: The Use of Structural Information to Understand Binding Kinetics. In: Thermodynamics and Kinetics of Drug Binding. Wiley-VCH Verlag GmbH & Co. KGaA, (2015)

  • [9]R. A. Copeland: Conformational adaptation in drug-target interactions and residence time. Future Med Chem, 3 (12), 1491-501 (2011)

  • [10]D. D. Boehr, R. Nussinov and P. E. Wright: The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol, 5 (11), 789-96 (2009)

  • [11]V. L. Schramm: Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes. Annu Rev Biochem, 80, 703-32 (2011)

  • [12]N. Jura, X. Zhang, N. F. Endres, M. A. Seeliger, T. Schindler and J. Kuriyan: Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell, 42 (1), 9-22 (2011)

  • [13]M. Tong and M. A. Seeliger: Targeting conformational plasticity of protein kinases. ACS Chem Biol, 10 (1), 190-200 (2015)

  • [14]S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, R. A. Smith, B. Schwartz, R. Simantov and S. Kelley: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5 (10), 835-44 (2006)

  • [15]S. M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L. E. Post, G. Bollag and P. A. Trail: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64 (19), 7099-109 (2004)

  • [16]P. T. C. Wan, M. J. Garnett, S. M. Roe, S. Lee, D. Niculescu-Duvaz, V. M. Good, C. G. Project, C. M. Jones, C. J. Marshall, C. J. Springer, D. Barford and R. Marais: Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell, 116 (6), 855-867 (2004)

  • [17]L. Neumann, K. von König and D. Ullmann: Chapter Twelve - HTS Reporter Displacement Assay for Fragment Screening and Fragment Evolution Toward Leads with Optimized Binding Kinetics, Binding Selectivity, and Thermodynamic Signature. In: Methods in Enzymology. Ed C. K. Lawrence. Academic Press, (2011)

  • [18]K. Okamoto, M. Ikemori-Kawada, A. Jestel, K. von König, Y. Funahashi, T. Matsushima, A. Tsuruoka, A. Inoue and J. Matsui: Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Medicinal Chemistry Letters, 6 (1), 89-94 (2015)

  • [19]K. Anderson, Z. Lai, Octerloney B. Mcdonald, J. D. Stuart, Eldridge N. Nartey, Mary A. Hardwicke, K. Newlander, D. Dhanak, J. Adams, D. Patrick, Robert A. Copeland, Peter J. Tummino and J. Yang: Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. (2009)

  • [20]L. T. Alexander, H. Möbitz, P. Drueckes, P. Savitsky, O. Fedorov, J. M. Elkins, C. M. Deane, S. W. Cowan-Jacob and S. Knapp: Type II Inhibitors Targeting CDK2. ACS Chemical Biology (2015)

  • [21]D. C. Miller, G. Lunn, P. Jones, Y. Sabnis, N. L. Davies and P. Driscoll: Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target. MedChemComm, 3 (4), 449-452 (2012)

  • [22]E. R. Wood, A. T. Truesdale, O. B. McDonald, D. Yuan, A. Hassell, S. H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K. J. Alligood, D. W. Rusnak, T. M. Gilmer and L. Shewchuk: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res, 64 (18), 6652-9 (2004)

  • [23]A. W. Barb and P. Zhou: Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr Pharm Biotechnol, 9 (1), 9-15 (2008)

  • [24]J. S. Warmus, C. L. Quinn, C. Taylor, S. T. Murphy, T. A. Johnson, C. Limberakis, D. Ortwine, J. Bronstein, P. Pagano, J. D. Knafels, S. Lightle, I. Mochalkin, R. Brideau and T. Podoll: Structure based design of an in vivo active hydroxamic acid inhibitor of P.aeruginosa LpxC. Bioorganic & Medicinal Chemistry Letters, 22 (7), 2536-2543 (2012)

  • [25]A. W. Barb, L. Jiang, C. R. Raetz and P. Zhou: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci U S A, 104 (47), 18433-8 (2007)

  • [26]G. K. Walkup, Z. You, P. L. Ross, E. K. Allen, F. Daryaee, M. R. Hale, J. O’Donnell, D. E. Ehmann, V. J. Schuck, E. T. Buurman, A. L. Choy, L. Hajec, K. Murphy-Benenato, V. Marone, S. A. Patey, L. A. Grosser, M. Johnstone, S. G. Walker, P. J. Tonge and S. L. Fisher: Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat Chem Biol, 11 (6), 416-23 (2015)

  • [27]F. van Leeuwen, P. R. Gafken and D. E. Gottschling: Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell, 109 (6), 745-56 (2002)

  • [28]Y. Okada, Q. Feng, Y. Lin, Q. Jiang, Y. Li, V. M. Coffield, L. Su, G. Xu and Y. Zhang: hDOT1L Links Histone Methylation to Leukemogenesis. Cell, 121 (2), 167-178 (2005)

  • [29]S. R. Daigle, E. J. Olhava, C. A. Therkelsen, C. R. Majer, C. J. Sneeringer, J. Song, L. D. Johnston, M. P. Scott, J. J. Smith, Y. Xiao, L. Jin, K. W. Kuntz, R. Chesworth, M. P. Moyer, K. M. Bernt, J. C. Tseng, A. L. Kung, S. A. Armstrong, R. A. Copeland, V. M. Richon and R. M. Pollock: Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell, 20 (1), 53-65 (2011)

  • [30]A. Basavapathruni, L. Jin, S. R. Daigle, C. R. Majer, C. A. Therkelsen, T. J. Wigle, K. W. Kuntz, R. Chesworth, R. M. Pollock, M. P. Scott, M. P. Moyer, V. M. Richon, R. A. Copeland and E. J. Olhava: Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des, 80 (6), 971-80 (2012)

  • [31]S. R. Daigle, E. J. Olhava, C. A. Therkelsen, A. Basavapathruni, L. Jin, P. A. Boriack-Sjodin, C. J. Allain, C. R. Klaus, A. Raimondi, M. P. Scott, N. J. Waters, R. Chesworth, M. P. Moyer, R. A. Copeland, V. M. Richon and R. M. Pollock: Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. (2013)

  • [32]P. Schmidtke, F. J. Luque, J. B. Murray and X. Barril: Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. J Am Chem Soc, 133 (46), 18903-10 (2011)

  • [33]C. Bissantz, B. Kuhn and M. Stahl: A Medicinal Chemist’s Guide to Molecular Interactions. Journal of Medicinal Chemistry, 53 (14), 5061-5084 (2010)

  • [34]E. V. Schneider, J. Bottcher, M. Blaesse, L. Neumann, R. Huber and K. Maskos: The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. J Mol Biol, 412 (2), 251-66 (2011)

  • [35]E. V. Schneider, J. Bottcher, R. Huber, K. Maskos and L. Neumann: Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc Natl Acad Sci U S A, 110 (20), 8081-6 (2013)

  • [36]A. P. Kornev, N. M. Haste, S. S. Taylor and L. F. Eyck: Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A, 103 (47), 17783-8 (2006)

  • [37]A. M. Aronov, Q. Tang, G. Martinez-Botella, G. W. Bemis, J. Cao, G. Chen, N. P. Ewing, P. J. Ford, U. A. Germann, J. Green, M. R. Hale, M. Jacobs, J. W. Janetka, F. Maltais, W. Markland, M. N. Namchuk, S. Nanthakumar, S. Poondru, J. Straub, E. ter Haar and X. Xie: Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem, 52 (20), 6362-8 (2009)

  • [38]E. J. Morris, S. Jha, C. R. Restaino, P. Dayananth, H. Zhu, A. Cooper, D. Carr, Y. Deng, W. Jin, S. Black, B. Long, J. Liu, E. Dinunzio, W. Windsor, R. Zhang, S. Zhao, M. H. Angagaw, E. M. Pinheiro, J. Desai, L. Xiao, G. Shipps, A. Hruza, J. Wang, J. Kelly, S. Paliwal, X. Gao, B. S. Babu, L. Zhu, P. Daublain, L. Zhang, B. A. Lutterbach, M. R. Pelletier, U. Philippar, P. Siliphaivanh, D. Witter, P. Kirschmeier, W. R. Bishop, D. Hicklin, D. G. Gilliland, L. Jayaraman, L. Zawel, S. Fawell and A. A. Samatar: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov, 3 (7), 742-50 (2013)

  • [39]A. Chaikuad, E. M. Tacconi, J. Zimmer, Y. Liang, N. S. Gray, M. Tarsounas and S. Knapp: A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol, 10 (10), 853-60 (2014)

  • [40]M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge, B. T. Campbell, K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J. Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M. Wodicka and P. P. Zarrinkar: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol, 26 (1), 127-32 (2008)

  • [41]W. Bode: Structure and interaction modes of thrombin. Blood Cells, Molecules, and Diseases, 36 (2), 122-130 (2006)

  • [42]T. Nilsson, Å. Sjöling-Ericksson and J. Deinum: The Mechanism of Binding of Low-Molecular-Weight Active Site Inhibitors to Human α-Thrombin. Journal of Enzyme Inhibition, 13 (1), 11-29 (1998)

  • [43]J. Winquist, S. Geschwindner, Y. Xue, L. Gustavsson, D. Musil, J. Deinum and U. H. Danielson: Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors. Biochemistry, 52 (4), 613-26 (2013)

  • [44]A. Biela, F. Sielaff, F. Terwesten, A. Heine, T. Steinmetzer and G. Klebe: Ligand binding stepwise disrupts water network in thrombin: enthalpic and entropic changes reveal classical hydrophobic effect. J Med Chem, 55 (13), 6094-110 (2012)

  • [45]A. Sarkar and G. E. Kellogg: Hydrophobicity – Shake Flasks, Protein Folding and Drug Discovery. Current topics in medicinal chemistry, 10 (1), 67-83 (2010)

  • [46]P. Setny, R. Baron, P. Michael Kekenes-Huskey, J. A. McCammon and J. Dzubiella: Solvent fluctuations in hydrophobic cavity-ligand binding kinetics. Proc Natl Acad Sci U S A, 110 (4), 1197-202 (2013)

  • [47]A. C. Pan, D. W. Borhani, R. O. Dror and D. E. Shaw: Molecular determinants of drug–receptor binding kinetics. Drug Discovery Today, 18 (13–14), 667-673 (2013)

  • [48]J. F. Chen, H. K. Eltzschig and B. B. Fredholm: Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov, 12 (4), 265-86 (2013)

  • [49]D. Guo, T. Mulder-Krieger, I. J. AP and L. H. Heitman: Functional efficacy of adenosine A (2)A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol, 166 (6), 1846-59 (2012)

  • [50]P. A. Borea, A. Dalpiaz, K. Varani, S. Gessi and G. Gilli: Binding thermodynamics at A1 and A2A adenosine receptors. Life Sci, 59 (17), 1373-88 (1996)

  • [51]J. Singh, R. C. Petter, T. A. Baillie and A. Whitty: The resurgence of covalent drugs. Nat Rev Drug Discov, 10 (4), 307-17 (2011)

  • [52]R. Mah, J. R. Thomas and C. M. Shafer: Drug discovery considerations in the development of covalent inhibitors. Bioorganic & Medicinal Chemistry Letters, 24 (1), 33-39 (2014)

  • [53]J. R. Vane and R. M. Botting: The mechanism of action of aspirin. Thrombosis Research, 110 (5–6), 255-258 (2003)

  • [54]J. R. Vane: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 231, 232-5 (1971)

  • [55]P. J. Loll, D. Picot and R. M. Garavito: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol, 2 (8), 637-43 (1995)

  • [56]R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong and C. Lin: Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother, 50 (3), 899-909 (2006)

  • [57]J. B. Petro, S. M. J. Rahman, D. W. Ballard and W. N. Khan: Bruton’s Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement. The Journal of Experimental Medicine, 191 (10), 1745-1754 (2000)

  • [58]S. Ponader, S. S. Chen, J. J. Buggy, K. Balakrishnan, V. Gandhi, W. G. Wierda, M. J. Keating, S. O’Brien, N. Chiorazzi and J. A. Burger: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119 (5), 1182-9 (2012)

  • [59]J. M. Bradshaw, J. M. McFarland, V. O. Paavilainen, A. Bisconte, D. Tam, V. T. Phan, S. Romanov, D. Finkle, J. Shu, V. Patel, T. Ton, X. Li, D. G. Loughhead, P. A. Nunn, D. E. Karr, M. E. Gerritsen, J. O. Funk, T. D. Owens, E. Verner, K. A. Brameld, R. J. Hill, D. M. Goldstein and J. Taunton: Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol, advance online publication (2015)

  • [60]W. D. Paton and H. P. Rang: The Uptake of Atropine and Related Drugs by Intestinal Smooth Muscle of the Guinea-Pig in Relation to Acetylcholine Receptors. Proc R Soc Lond B Biol Sci, 163, 1-44 (1965)

  • [61]W. D. M. Paton and D. R. Waud: A quantitative investigation of the relationship between rate of access of a drug to receptor and the rate of onset or offset of action. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 248 (2), 124-143 (1964)

  • [62]W. D. M. Paton: Kinetic theories of drug action with special reference to the acetylcholine group of agonists and antagonists. Annals of the New York Academy of Sciences, 144 (2), 869-881 (1967)

  • [63]G. Segre: Radioisotopes in the study of drugs kinetics. J Nucl Biol Med, 12 (1), 1-4 (1968)

  • [64]G. A. Weiland and P. B. Molinoff: Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci, 29 (4), 313-30 (1981)

  • [65]N. Rietbrock and A. Lassmann: Stopped-flow studies on drug-protein binding. 1. Kinetics of warfarin binding to human serum albumin. Naunyn Schmiedebergs Arch Pharmacol, 313 (3), 269-74 (1980)

  • [66]V. Maes, Y. Engelborghs, J. Hoebeke, Y. Maras and A. Vercruysse: Fluorimetric analysis of the binding of warfarin to human serum albumin. Equilibrium and kinetic study. Mol Pharmacol, 21 (1), 100-7 (1982)

  • [67]T. Endo, M. Nakanishi, S. Furukawa, F. J. Joubert, N. Tamiya and K. Hayashi: Stopped-flow fluorescence studies on binding kinetics of neurotoxins with acetylcholine receptor. Biochemistry, 25 (2), 395-404 (1986)

  • [68]M. L. Contreras, B. B. Wolfe and P. B. Molinoff: Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther, 239 (1), 136-43 (1986)

  • [69]J. E. Hawkinson and J. E. Casida: Binding kinetics of gamma-aminobutyric acidA receptor noncompetitive antagonists: trioxabicyclooctane, dithiane, and cyclodiene insecticide-induced slow transition to blocked chloride channel conformation. Mol Pharmacol, 42 (6), 1069-76 (1992)

  • [70]T. C. VanCott, L. D. Loomis, R. R. Redfield and D. L. Birx: Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J Immunol Methods, 146 (2), 163-76 (1992)

  • [71]D. Altschuh, M. C. Dubs, E. Weiss, G. Zeder-Lutz and M. H. Van Regenmortel: Determination of kinetic constants for the interaction between a monoclonal antibody and peptides using surface plasmon resonance. Biochemistry, 31 (27), 6298-304 (1992)

  • [72]R. Karlsson: Real-time competitive kinetic analysis of interactions between low-molecular-weight ligands in solution and surface-immobilized receptors. Anal Biochem, 221 (1), 142-51 (1994)

  • [73]M. Hara, F. Tozawa, K. Itazaki, S. Mihara and M. Fujimoto: Endothelin ET (B) receptors show different binding profiles in intact cells and cell membrane preparations. Eur J Pharmacol, 345 (3), 339-42 (1998)

  • [74]F. L. Fierens, P. M. Vanderheyden, C. Roggeman, P. Vande Gucht, J. P. De Backer and G. Vauquelin: Distinct binding properties of the AT (1) receptor antagonist (3)H)candesartan to intact cells and membrane preparations. Biochem Pharmacol, 63 (7), 1273-9 (2002)

  • [75]A. Packeu, J. P. De Backer, I. Van Liefde, P. M. Vanderheyden and G. Vauquelin: Antagonist-radioligand binding to D2L-receptors in intact cells. Biochem Pharmacol, 75 (11), 2192-203 (2008)

  • [76]K. E. Luker, L. A. Mihalko, B. T. Schmidt, S. A. Lewin, P. Ray, D. Shcherbo, D. M. Chudakov and G. D. Luker: In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nat Med, 18 (1), 172-7 (2012)

  • [77]F. Schiele, P. Ayaz and A. Fernandez-Montalvan: A universal homogeneous assay for high-throughput determination of binding kinetics. Anal Biochem, 468C, 42-49 (2014)

  • [78]L. A. Stoddart, E. K. Johnstone, A. J. Wheal, J. Goulding, M. B. Robers, T. Machleidt, K. V. Wood, S. J. Hill and K. D. Pfleger: Application of BRET to monitor ligand binding to GPCRs. Nat Methods, 12 (7), 661-3 (2015)

  • [79]S. J. Ramsey, N. J. Attkins, R. Fish and P. H. van der Graaf: Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br J Pharmacol, 164 (3), 992-1007 (2011)

  • [80]S. Kapur and P. Seeman: Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci, 25 (2), 161-6 (2000)

  • [81]N. Ginovart, W. Sun, A. A. Wilson, S. Houle and S. Kapur: Quantitative validation of an intracerebral beta-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using (11C)raclopride in rats. Synapse, 52 (2), 89-99 (2004)

  • [82]N. Thorne, D. S. Auld and J. Inglese: Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr Opin Chem Biol, 14 (3), 315-24 (2010)

  • [83]R. A. Copeland, A. Basavapathruni, M. Moyer and M. P. Scott: Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Anal Biochem, 416 (2), 206-10 (2011)

  • [84]J. R. Simard, C. Grutter, V. Pawar, B. Aust, A. Wolf, M. Rabiller, S. Wulfert, A. Robubi, S. Kluter, C. Ottmann and D. Rauh: High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. J Am Chem Soc, 131 (51), 18478-88 (2009)

  • [85]J. R. Simard, M. Getlik, C. Grutter, R. Schneider, S. Wulfert and D. Rauh: Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. J Am Chem Soc, 132 (12), 4152-60 (2010)

  • [86]J. Louvel, D. Guo, M. Agliardi, T. A. Mocking, R. Kars, T. P. Pham, L. Xia, H. de Vries, J. Brussee, L. H. Heitman and A. P. Ijzerman: Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. J Med Chem, 57 (8), 3213-22 (2014)

  • [87]D. C. Swinney, P. Beavis, K. T. Chuang, Y. Zheng, I. Lee, P. Gee, J. Deval, D. M. Rotstein, M. Dioszegi, P. Ravendran, J. Zhang, S. Sankuratri, R. Kondru and G. Vauquelin: A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br J Pharmacol, 171 (14), 3364-75 (2014)

  • [88]J. P. van Veldhoven, R. Liu, S. A. Thee, Y. Wouters, S. J. Verhoork, C. Mooiman, J. Louvel and I. J. AP: Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists. Bioorg Med Chem, 23 (14), 4013-25 (2015)

  • [89]K. Okamoto, M. Ikemori-Kawada, A. Jestel, K. von Konig, Y. Funahashi, T. Matsushima, A. Tsuruoka, A. Inoue and J. Matsui: Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett, 6 (1), 89-94 (2015)

  • [90]C. Meyners, M. G. Baud, M. J. Fuchter and F. J. Meyer-Almes: Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors. Anal Biochem, 460, 39-46 (2014)

  • [91]H. J. Motulsky and L. C. Mahan: The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol, 25 (1), 1-9 (1984)

  • [92]N. Granqvist, A. Hanning, L. Eng, J. Tuppurainen and T. Viitala: Label-enhanced surface plasmon resonance: a new concept for improved performance in optical biosensor analysis. Sensors (Basel), 13 (11), 15348-63 (2013)

  • [93]D. Guo, J. M. Hillger, I. J. AP and L. H. Heitman: Drug-target residence time--a case for G protein-coupled receptors. Med Res Rev, 34 (4), 856-92 (2014)

  • [94]C. E. Heise, S. K. Sullivan and P. D. Crowe: Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen, 12 (2), 235-9 (2007)

  • [95]D. Vanderpool, C. E. Grimshaw, J. D. Lawson and J. Ermolieff: Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors. Anal Biochem, 473, 46-52 (2015)

  • [96]D. Guo, E. J. van Dorp, T. Mulder-Krieger, J. P. van Veldhoven, J. Brussee, A. P. Ijzerman and L. H. Heitman: Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen, 18 (3), 309-20 (2013)

  • [97]L. Neumann, A. Ritscher, G. Muller and D. Hafenbradl: Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology. J Comput Aided Mol Des, 23 (8), 501-11 (2009)

  • [98]J. C. Uitdehaag, C. M. Sunnen, A. M. van Doornmalen, N. de Rouw, A. Oubrie, R. Azevedo, M. Ziebell, E. Nickbarg, W. J. Karstens and S. Ruygrok: Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way. J Biomol Screen, 16 (9), 1007-17 (2011)

  • [99]R. A. Copeland: Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal, 46, 1-265 (2005)

  • [100]A. C. Cheng and I. H. Tsai: Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell’s viper venom. Biochim Biophys Acta, 1840 (1), 153-9 (2014)

  • [101]A. Wang, C. Dorso, L. Kopcho, G. Locke, R. Langish, E. Harstad, P. Shipkova, J. Marcinkeviciene, L. Hamann and M. S. Kirby: Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol, 12, 2 (2012)

  • [102]Q. Liu, S. Kirubakaran, W. Hur, M. Niepel, K. Westover, C. C. Thoreen, J. Wang, J. Ni, M. P. Patricelli, K. Vogel, S. Riddle, D. L. Waller, R. Traynor, T. Sanda, Z. Zhao, S. A. Kang, J. Zhao, A. T. Look, P. K. Sorger, D. M. Sabatini and N. S. Gray: Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem, 287 (13), 9742-52 (2012)

  • [103]R. A. Copeland: Tight Binding Inhibitors. In: Enzymes. John Wiley & Sons, Inc., (2002)

  • [104]R. A. Copeland: Time-Dependent Inhibition. In: Enzymes. John Wiley & Sons, Inc., (2002)

  • [105]R. Zhang and W. T. Windsor: In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis. Methods Mol Biol, 1030, 59-79 (2013)

  • [106]T. Kenakin, S. Jenkinson and C. Watson: Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther, 319 (2), 710-23 (2006)

  • [107]J. Gatfield, C. Mueller Grandjean, T. Sasse, M. Clozel and O. Nayler: Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One, 7 (10), e47662 (2012)

  • [108]D. Hafenbradl, M. Baumann and L. Neumann: In vitro Characterization of Small-Molecule Kinase Inhibitors. In: Protein Kinases as Drug Targets. Wiley-VCH Verlag GmbH & Co. KGaA, (2011)

  • [109]J. Borovska, V. Vyklicky, E. Stastna, V. Kapras, B. Slavikova, M. Horak, H. Chodounska and L. Vyklicky, Jr.: Access of inhibitory neurosteroids to the NMDA receptor. Br J Pharmacol, 166 (3), 1069-83 (2012)

  • [110]B. Tillotson, J. Coco, N. Whitebread, K. West, K. Slocum, B. Thomas, J. Ge, J. Ali, E. Normant, J. Hoyt, J. MacDougall, J. Sydor, V. Palombella, J. Adams and C. Fritz: Abstract #1710: A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors. Cancer Research, 69 (9 Supplement), 1710 (2009)

  • [111]D. S. Auld, M. W. Farmen, S. D. Kahl, A. Kriauciunas, K. L. McKnight, C. Montrose and J. R. Weidner: Receptor Binding Assays for HTS and Drug Discovery. In: Assay Guidance Manual. Ed G. S. Sittampalam, N. P. Coussens, H. Nelson, M. Arkin, D. Auld, C. Austin, B. Bejcek, M. Glicksman, J. Inglese, P. W. Iversen, Z. Li, J. McGee, O. McManus, L. Minor, A. Napper, J. M. Peltier, T. Riss, O. J. Trask, Jr.&J. Weidner. Bethesda (MD) (2004)

  • [112]G. Vauquelin, S. Bostoen, P. Vanderheyden and P. Seeman: Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol, 385 (4), 337-72 (2012)

  • [113]N. Bocquet, J. Kohler, M. N. Hug, E. A. Kusznir, A. C. Rufer, R. J. Dawson, M. Hennig, A. Ruf, W. Huber and S. Huber: Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance. Biochim Biophys Acta, 1848 (5), 1224-33 (2015)

  • [114]D. E. Raines and N. S. Krishnan: Transient low-affinity agonist binding to Torpedo postsynaptic membranes resolved by using sequential mixing stopped-flow fluorescence spectroscopy. Biochemistry, 37 (3), 956-64 (1998)

  • [115]O. Barauskas, A. C. Corsa, R. Wang, S. Hluhanich, D. Jin, M. Hung, H. Yang, W. E. t. Delaney and B. E. Schultz: Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir. Biochim Biophys Acta, 1840 (12), 3292-8 (2014)

  • [116]I. E. Andreeva, S. Nirthanan, J. B. Cohen and S. E. Pedersen: Site specificity of agonist-induced opening and desensitization of the Torpedo californica nicotinic acetylcholine receptor. Biochemistry, 45 (1), 195-204 (2006)

  • [117]P. van der Sluijs, B. Postema and D. K. Meijer: Lactosylation of albumin reduces uptake rate of dibromosulfophthalein in perfused rat liver and dissociation rate from albumin in vitro. Hepatology, 7 (4), 688-95 (1987)

  • [118]L. T. May, S. J. Briddon and S. J. Hill: Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions. Mol Pharmacol, 77 (4), 678-86 (2010)

  • [119]L. T. May, T. J. Self, S. J. Briddon and S. J. Hill: The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Mol Pharmacol, 78 (3), 511-23 (2010)

  • [120]G. Turcatti, H. Vogel and A. Chollet: Probing the binding domain of the NK2 receptor with fluorescent ligands: evidence that heptapeptide agonists and antagonists bind differently. Biochemistry, 34 (12), 3972-80 (1995)

  • [121]I. Nederpelt, V. Schuldt, F. Schiele, K. Nowak-Reppel, A. E. Fernandez-Montalvan, I. J. AP and L. H. Heitman: Characterization of 12 GnRH peptide agonists - a kinetic perspective. Br J Pharmacol (2015)

  • [122]J. L. Mason, C. Spais, J. Husten, E. Prouty, M. S. Albom, S. L. Meyer, M. A. Ator and T. S. Angeles: Comparison of LanthaScreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors. Assay Drug Dev Technol, 10 (5), 468-75 (2012)

  • [123]D. Riester, C. Hildmann, A. Schwienhorst and F. J. Meyer-Almes: Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer. Anal Biochem, 362 (1), 136-41 (2007)

  • [124]T. Brauns, Z. W. Cai, S. D. Kimball, K. C. Kang, R. P. Haugland, W. Berger, S. Berjukov, S. Hering, H. Glossmann and J. Striessnig: Benzothiazepine binding domain of purified L-type calcium channels: direct labeling using a novel fluorescent diltiazem analogue. Biochemistry, 34 (10), 3461-9 (1995)

  • [125]K. D. Pfleger and K. A. Eidne: Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods, 3 (3), 165-74 (2006)

  • [126]N. Boute, R. Jockers and T. Issad: The use of resonance energy transfer in high-throughput screening: BRET versus FRET. Trends Pharmacol Sci, 23 (8), 351-4 (2002)

  • [127]E. Segala, J. C. Errey, C. Fiez-Vandal, A. Zhukov and R. M. Cooke: Biosensor-based affinities and binding kinetics of small molecule antagonists to the adenosine A (2A) receptor reconstituted in HDL like particles. FEBS Lett, 589 (13), 1399-405 (2015)

  • [128]T. Aristotelous, S. Ahn, A. K. Shukla, S. Gawron, M. F. Sassano, A. W. Kahsai, L. M. Wingler, X. Zhu, P. Tripathi-Shukla, X. P. Huang, J. Riley, J. Besnard, K. D. Read, B. L. Roth, I. H. Gilbert, A. L. Hopkins, R. J. Lefkowitz and I. Navratilova: Discovery of beta2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Med Chem Lett, 4 (10), 1005-1010 (2013)

  • [129]M. J. Serrano-Vega, F. Magnani, Y. Shibata and C. G. Tate: Conformational thermostabilization of the beta1-adrenergic receptor in a detergent-resistant form. Proc Natl Acad Sci U S A, 105 (3), 877-82 (2008)

  • [130]N. B. Shah and T. M. Duncan: Bio-layer interferometry for measuring kinetics of protein-protein interactions and allosteric ligand effects. J Vis Exp (84), e51383 (2014)

  • [131]R. G. Heym, W. B. Hornberger, V. Lakics and G. C. Terstappen: Label-free detection of small-molecule binding to a GPCR in the membrane environment. Biochim Biophys Acta, 1854 (8), 979-86 (2015)

  • [132]O. P. Hamill, A. Marty, E. Neher, B. Sakmann and F. J. Sigworth: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch, 391 (2), 85-100 (1981)

  • [133]P. S. Hasenhuetl, K. Schicker, X. Koenig, Y. Li, S. Sarker, T. Stockner, S. Sucic, H. H. Sitte, M. Freissmuth and W. Sandtner: Ligand Selectivity among the Dopamine and Serotonin Transporters Specified by the Forward Binding Reaction. Mol Pharmacol, 88 (1), 12-8 (2015)

  • [134]A. Chang, K. Kapilashrami, E. K. H. Allen and P. J. Tonge: The Kinetics and Thermodynamics of Staphylococcus aureus FabI Inhibition. In: Thermodynamics and Kinetics of Drug Binding. Wiley-VCH Verlag GmbH & Co. KGaA, (2015)

  • [135]D. Tolkatchev, P. Xu and F. Ni: Probing the kinetic landscape of transient peptide-protein interactions by use of peptide (15)n NMR relaxation dispersion spectroscopy: binding of an antithrombin peptide to human prothrombin. J Am Chem Soc, 125 (41), 12432-42 (2003)

  • [136]D. F. Hansen, Z. Zhou, H. Feng, L. M. Miller Jenkins, Y. Bai and L. E. Kay: Binding kinetics of histone chaperone Chz1 and variant histone H2A.Z-H2B by relaxation dispersion NMR spectroscopy. J Mol Biol, 387 (1), 1-9 (2009)

  • [137]P. Tiwary, V. Limongelli, M. Salvalaglio and M. Parrinello: Kinetics of protein–ligand unbinding: Predicting pathways, rates, and rate-limiting steps. Proceedings of the National Academy of Sciences, 112 (5), E386-E391 (2015)

  • [138]Y. M. Huang, M. Kang and C. E. Chang: Switches of hydrogen bonds during ligand-protein association processes determine binding kinetics. J Mol Recognit, 27 (9), 537-48 (2014)

  • [139]J. R. Galvin, M. Mori and W. Stanford: High-resolution computed tomography and diffuse lung disease. Curr Probl Diagn Radiol, 21 (2), 31-74 (1992)

  • [140]L. S. Halperin and L. H. Schoch: Angle closure glaucoma after scleral buckling for retinopathy of prematurity. Case report. Arch Ophthalmol, 106 (4), 453 (1988)

  • [141]H. Deng, C. Wang, M. Su and Y. Fang: Probing biochemical mechanisms of action of muscarinic M3 receptor antagonists with label-free whole cell assays. Anal Chem, 84 (19), 8232-9 (2012)

  • [142]R. E. Kunz and K. Cottier: Optimizing integrated optical chips for label-free (bio-)chemical sensing. Anal Bioanal Chem, 384 (1), 180-90 (2006)

  • [143]P. Kozma, A. Hamori, K. Cottier, S. Kurunczi and R. Horvath: Grating coupled interferometry for optical sensing. Applied Physics B, 97 (1), 5-8 (2009)

  • [144]D. J. Bornhop, J. C. Latham, A. Kussrow, D. A. Markov, R. D. Jones and H. S. Sorensen: Free-solution, label-free molecular interactions studied by back-scattering interferometry. Science, 317 (5845), 1732-6 (2007)

  • [145]X. Duan, Y. Li, N. K. Rajan, D. A. Routenberg, Y. Modis and M. A. Reed: Quantification of the affinities and kinetics of protein interactions using silicon nanowire biosensors. Nat Nanotechnol, 7 (6), 401-7 (2012)

  • [146]R. Schroder, J. Schmidt, S. Blattermann, L. Peters, N. Janssen, M. Grundmann, W. Seemann, D. Kaufel, N. Merten, C. Drewke, J. Gomeza, G. Milligan, K. Mohr and E. Kostenis: Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc, 6 (11), 1748-60 (2011)

  • [147]D. Burnouf, E. Ennifar, S. Guedich, B. Puffer, G. Hoffmann, G. Bec, F. Disdier, M. Baltzinger and P. Dumas: kinITC: A New Method for Obtaining Joint Thermodynamic and Kinetic Data by Isothermal Titration Calorimetry. Journal of the American Chemical Society, 134 (1), 559-565 (2012)

  • [148]M. Kanoatov, L. T. Cherney and S. N. Krylov: Extracting kinetics from affinity capillary electrophoresis (ACE) data: a new blade for the old tool. Anal Chem, 86 (2), 1298-305 (2014)

  • [149]R. C. Blake, 2nd, A. R. Pavlov and D. A. Blake: Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. Anal Biochem, 272 (2), 123-34 (1999)

  • [150]A. W. Drake, M. L. Tang, G. A. Papalia, G. Landes, M. Haak-Frendscho and S. L. Klakamp: Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. Anal Biochem, 429 (1), 58-69 (2012)

  • [151]C. Bee, Y. N. Abdiche, D. M. Stone, S. Collier, K. C. Lindquist, A. C. Pinkerton, J. Pons and A. Rajpal: Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. PLoS One, 7 (4), e36261 (2012)

  • [152]T. Wunberg, M. Hendrix, A. Hillisch, M. Lobell, H. Meier, C. Schmeck, H. Wild and B. Hinzen: Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov Today, 11 (3-4), 175-80 (2006)

  • [153]L. M. Mayr and D. Bojanic: Novel trends in high-throughput screening. Curr Opin Pharmacol, 9 (5), 580-8 (2009)

  • [154]J. Yang, R. A. Copeland and Z. Lai: Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J Biomol Screen, 14 (2), 111-20 (2009)

  • [155]D. Guo, L. H. Heitman and A. P. Ijzerman: The Role of Target Binding Kinetics in Drug Discovery. ChemMedChem, n/a-n/a (2015)

  • [156]B. Schwanhausser, D. Busse, N. Li, G. Dittmar, J. Schuchhardt, J. Wolf, W. Chen and M. Selbach: Global quantification of mammalian gene expression control. Nature, 473 (7347), 337-42 (2011)

  • [157]J. G. Cumming, M. R. Finlay, F. Giordanetto, M. Hemmerling, T. Lister, H. Sanganee and M. J. Waring: Potential strategies for increasing drug-discovery productivity. Future Med Chem, 6 (5), 515-27 (2014)

  • [158]M. B. Robers, M. L. Dart, C. C. Woodroofe, C. A. Zimprich, T. A. Kirkland, T. Machleidt, K. R. Kupcho, S. Levin, J. R. Hartnett, K. Zimmerman, A. L. Niles, R. Friedman Ohana1, D. L. Daniels, M. Slater, M. G. Wood, M. Cong, Y.-Q. Cheng and K. V. Wood: Target engagement and drug residence time can be observed in living cells with BRET. Nat Communications, 6 (10091), 1-10 (2015)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review

Binding kinetics in drug discovery – A current perspective

Victoria Georgi 1, Dorothee Andres 1, Amaury E. Fernandez-Montalvan 1, Christian M. Stegmann 1, Andreas Becker 1, Anke Mueller-Fahrnow 1,*
Affiliation
Article Info

1 Bayer Pharma AG, Lead Discovery Berlin, Muellerstrasse 178, 13353 Berlin, Germany

Abstract

The impact of target binding kinetics (BK) on the clinical performance of therapeutic agents is presently a topic of intense debate in drug discovery. While retrospective studies suggest that BK is a differentiating parameter in marketed medicines, it is yet unclear how this information could be used to prioritize drug candidates during lead optimization. Motivated by the question whether BK can be understood and rationally optimized, we review the most relevant literature in the field, with special focus on selected examples from our organization. First we discuss structure-kinetic relationships (SKR), and how they can be influenced by factors such as conformational changes, molecular flexibility, hydrogen bonds, hydrophobicity, water molecules and (reversible-) covalent bonds. We then introduce the methodologies currently used for the investigation of BK parameters, briefly commenting on their strengths, weaknesses and future trends. Finally, we present our current perspective on the integration of BK in the drug discovery process, aiming to stimulate further thoughts on this important subject.

Keywords

  • Binding Kinetics
  • Residence Time
  • Structure-Kinetic Relationships
  • On-Rate
  • Off-Rate
  • Review

References